Which has stronger valuation and earnings, VOR or RCKT?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vor Biopharma N/A N/A N/A N/A N/A Rocket Pharmaceuticals N/A N/A -$223.12M -$0.17 N/A

Is VOR or RCKT more profitable?

Vor Biopharma's return on equity of 0.00% beat Rocket Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Vor Biopharma N/A N/A N/A Rocket Pharmaceuticals N/A -52.77% -44.92%

Does the media prefer VOR or RCKT?

In the previous week, Rocket Pharmaceuticals had 14 more articles in the media than Vor Biopharma. MarketBeat recorded 16 mentions for Rocket Pharmaceuticals and 2 mentions for Vor Biopharma. Vor Biopharma's average media sentiment score of 0.91 beat Rocket Pharmaceuticals' score of 0.25 indicating that Vor Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vor Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rocket Pharmaceuticals 2 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate RCKT or CVAC?

Rocket Pharmaceuticals presently has a consensus target price of $7.77, indicating a potential upside of 237.92%. Given Rocket Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Rocket Pharmaceuticals is more favorable than CureVac. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rocket Pharmaceuticals 2 Sell rating(s) 4 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.42 CureVac 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media refer more to RCKT or IMTX?

In the previous week, Rocket Pharmaceuticals had 12 more articles in the media than Immatics. MarketBeat recorded 16 mentions for Rocket Pharmaceuticals and 4 mentions for Immatics. Rocket Pharmaceuticals' average media sentiment score of 0.25 beat Immatics' score of 0.25 indicating that Rocket Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rocket Pharmaceuticals 2 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Immatics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to RCKT or MGTX?

In the previous week, Rocket Pharmaceuticals had 11 more articles in the media than MeiraGTx. MarketBeat recorded 16 mentions for Rocket Pharmaceuticals and 5 mentions for MeiraGTx. MeiraGTx's average media sentiment score of 0.53 beat Rocket Pharmaceuticals' score of 0.25 indicating that MeiraGTx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rocket Pharmaceuticals 2 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral MeiraGTx 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Is JANX or RCKT more profitable?

Janux Therapeutics' return on equity of -11.89% beat Rocket Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Janux Therapeutics N/A -11.89% -11.13% Rocket Pharmaceuticals N/A -52.77% -44.92%

Does the media prefer JANX or RCKT?

In the previous week, Rocket Pharmaceuticals had 10 more articles in the media than Janux Therapeutics. MarketBeat recorded 16 mentions for Rocket Pharmaceuticals and 6 mentions for Janux Therapeutics. Janux Therapeutics' average media sentiment score of 0.57 beat Rocket Pharmaceuticals' score of 0.25 indicating that Janux Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Janux Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rocket Pharmaceuticals 2 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Rocket Pharmaceuticals (RCKT) Competitors

$2.30 -0.18 (-7.26%)

Closing price 10/13/2026 04:00 PM Eastern

Extended Trading

$2.32 +0.02 (+0.74%)

As of 10/13/2026 07:57 PM Eastern

Compare

RCKT vs. VOR, CVAC, IMTX, MGTX, and JANX

Should you buy Rocket Pharmaceuticals stock or one of its competitors? Rocket Pharmaceuticals's main competitors and comparable companies include Vor Biopharma (VOR), CureVac (CVAC), Immatics (IMTX), MeiraGTx (MGTX), and Janux Therapeutics (JANX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Rocket Pharmaceuticals compare to Vor Biopharma?

Vor Biopharma (NASDAQ:VOR) and Rocket Pharmaceuticals (NASDAQ:RCKT) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, valuation, profitability and media sentiment.

In the previous week, Rocket Pharmaceuticals had 14 more articles in the media than Vor Biopharma. MarketBeat recorded 16 mentions for Rocket Pharmaceuticals and 2 mentions for Vor Biopharma. Vor Biopharma's average media sentiment score of 0.91 beat Rocket Pharmaceuticals' score of 0.25 indicating that Vor Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vor Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rocket Pharmaceuticals	2 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Vor Biopharma's return on equity of 0.00% beat Rocket Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vor Biopharma	N/A	N/A	N/A
Rocket Pharmaceuticals	N/A	-52.77%	-44.92%

Vor Biopharma has a beta of 1.78, suggesting that its stock price is 78% more volatile than the broader market. Comparatively, Rocket Pharmaceuticals has a beta of 0.5, suggesting that its stock price is 50% less volatile than the broader market.

Vor Biopharma presently has a consensus target price of $41.71, suggesting a potential upside of 118.86%. Rocket Pharmaceuticals has a consensus target price of $7.77, suggesting a potential upside of 237.92%. Given Rocket Pharmaceuticals' higher possible upside, analysts clearly believe Rocket Pharmaceuticals is more favorable than Vor Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vor Biopharma	0 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.90
Rocket Pharmaceuticals	2 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.42

97.3% of Vor Biopharma shares are owned by institutional investors. Comparatively, 98.4% of Rocket Pharmaceuticals shares are owned by institutional investors. 0.3% of Vor Biopharma shares are owned by insiders. Comparatively, 21.3% of Rocket Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vor Biopharma	N/A	N/A	N/A	N/A	N/A
Rocket Pharmaceuticals	N/A	N/A	-$223.12M	-$0.17	N/A

Summary

Vor Biopharma beats Rocket Pharmaceuticals on 6 of the 10 factors compared between the two stocks.

How does Rocket Pharmaceuticals compare to CureVac?

Rocket Pharmaceuticals (NASDAQ:RCKT) and CureVac (NASDAQ:CVAC) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability, media sentiment and risk.

CureVac has higher revenue and earnings than Rocket Pharmaceuticals. Rocket Pharmaceuticals is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rocket Pharmaceuticals	N/A	N/A	-$223.12M	-$0.17	N/A
CureVac	$70.74M	14.78	$175.50M	$0.72	6.47

Rocket Pharmaceuticals presently has a consensus target price of $7.77, indicating a potential upside of 237.92%. Given Rocket Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Rocket Pharmaceuticals is more favorable than CureVac.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rocket Pharmaceuticals	2 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.42
CureVac	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Rocket Pharmaceuticals has a beta of 0.5, meaning that its share price is 50% less volatile than the broader market. Comparatively, CureVac has a beta of 1.77, meaning that its share price is 77% more volatile than the broader market.

In the previous week, Rocket Pharmaceuticals had 16 more articles in the media than CureVac. MarketBeat recorded 16 mentions for Rocket Pharmaceuticals and 0 mentions for CureVac. Rocket Pharmaceuticals' average media sentiment score of 0.25 beat CureVac's score of 0.00 indicating that Rocket Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Rocket Pharmaceuticals	Neutral
CureVac	Neutral

CureVac has a net margin of 199.92% compared to Rocket Pharmaceuticals' net margin of 0.00%. CureVac's return on equity of -23.03% beat Rocket Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rocket Pharmaceuticals	N/A	-52.77%	-44.92%
CureVac	199.92%	-23.03%	-19.09%

98.4% of Rocket Pharmaceuticals shares are held by institutional investors. Comparatively, 17.3% of CureVac shares are held by institutional investors. 21.3% of Rocket Pharmaceuticals shares are held by insiders. Comparatively, 2.2% of CureVac shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Rocket Pharmaceuticals and CureVac tied by winning 8 of the 16 factors compared between the two stocks.

How does Rocket Pharmaceuticals compare to Immatics?

Rocket Pharmaceuticals (NASDAQ:RCKT) and Immatics (NASDAQ:IMTX) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, profitability, institutional ownership, media sentiment, valuation, earnings and analyst recommendations.

98.4% of Rocket Pharmaceuticals shares are owned by institutional investors. Comparatively, 64.4% of Immatics shares are owned by institutional investors. 21.3% of Rocket Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Immatics has higher revenue and earnings than Rocket Pharmaceuticals. Rocket Pharmaceuticals is trading at a lower price-to-earnings ratio than Immatics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rocket Pharmaceuticals	N/A	N/A	-$223.12M	-$0.17	N/A
Immatics	$54.60M	17.10	-$222.26M	-$1.86	N/A

Rocket Pharmaceuticals presently has a consensus price target of $7.77, indicating a potential upside of 237.92%. Immatics has a consensus price target of $19.67, indicating a potential upside of 187.95%. Given Rocket Pharmaceuticals' higher possible upside, equities research analysts plainly believe Rocket Pharmaceuticals is more favorable than Immatics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rocket Pharmaceuticals	2 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.42
Immatics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

In the previous week, Rocket Pharmaceuticals had 12 more articles in the media than Immatics. MarketBeat recorded 16 mentions for Rocket Pharmaceuticals and 4 mentions for Immatics. Rocket Pharmaceuticals' average media sentiment score of 0.25 beat Immatics' score of 0.25 indicating that Rocket Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rocket Pharmaceuticals	2 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Immatics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Rocket Pharmaceuticals has a net margin of 0.00% compared to Immatics' net margin of -495.71%. Immatics' return on equity of -47.41% beat Rocket Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rocket Pharmaceuticals	N/A	-52.77%	-44.92%
Immatics	-495.71%	-47.41%	-39.45%

Rocket Pharmaceuticals has a beta of 0.5, meaning that its share price is 50% less volatile than the broader market. Comparatively, Immatics has a beta of 1.36, meaning that its share price is 36% more volatile than the broader market.

Summary

Rocket Pharmaceuticals and Immatics tied by winning 8 of the 16 factors compared between the two stocks.

How does Rocket Pharmaceuticals compare to MeiraGTx?

Rocket Pharmaceuticals (NASDAQ:RCKT) and MeiraGTx (NASDAQ:MGTX) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, earnings, institutional ownership, profitability, valuation and risk.

In the previous week, Rocket Pharmaceuticals had 11 more articles in the media than MeiraGTx. MarketBeat recorded 16 mentions for Rocket Pharmaceuticals and 5 mentions for MeiraGTx. MeiraGTx's average media sentiment score of 0.53 beat Rocket Pharmaceuticals' score of 0.25 indicating that MeiraGTx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rocket Pharmaceuticals	2 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
MeiraGTx	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

MeiraGTx has a net margin of 19.87% compared to Rocket Pharmaceuticals' net margin of 0.00%. MeiraGTx's return on equity of 283.85% beat Rocket Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rocket Pharmaceuticals	N/A	-52.77%	-44.92%
MeiraGTx	19.87%	283.85%	29.39%

MeiraGTx has higher revenue and earnings than Rocket Pharmaceuticals. Rocket Pharmaceuticals is trading at a lower price-to-earnings ratio than MeiraGTx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rocket Pharmaceuticals	N/A	N/A	-$223.12M	-$0.17	N/A
MeiraGTx	$81.39M	11.73	-$114.20M	$0.71	14.00

Rocket Pharmaceuticals currently has a consensus target price of $7.77, suggesting a potential upside of 237.92%. MeiraGTx has a consensus target price of $24.71, suggesting a potential upside of 148.63%. Given Rocket Pharmaceuticals' higher probable upside, equities research analysts clearly believe Rocket Pharmaceuticals is more favorable than MeiraGTx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rocket Pharmaceuticals	2 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.42
MeiraGTx	0 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.78

98.4% of Rocket Pharmaceuticals shares are held by institutional investors. Comparatively, 67.5% of MeiraGTx shares are held by institutional investors. 21.3% of Rocket Pharmaceuticals shares are held by insiders. Comparatively, 7.4% of MeiraGTx shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Rocket Pharmaceuticals has a beta of 0.5, indicating that its stock price is 50% less volatile than the broader market. Comparatively, MeiraGTx has a beta of 1.35, indicating that its stock price is 35% more volatile than the broader market.

Summary

MeiraGTx beats Rocket Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

How does Rocket Pharmaceuticals compare to Janux Therapeutics?

Janux Therapeutics (NASDAQ:JANX) and Rocket Pharmaceuticals (NASDAQ:RCKT) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, risk, media sentiment, valuation, earnings, analyst recommendations, profitability and dividends.

Janux Therapeutics has a beta of 2.4, suggesting that its share price is 140% more volatile than the broader market. Comparatively, Rocket Pharmaceuticals has a beta of 0.5, suggesting that its share price is 50% less volatile than the broader market.

Janux Therapeutics has higher revenue and earnings than Rocket Pharmaceuticals. Rocket Pharmaceuticals is trading at a lower price-to-earnings ratio than Janux Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Janux Therapeutics	$10M	105.04	-$113.62M	-$1.64	N/A
Rocket Pharmaceuticals	N/A	N/A	-$223.12M	-$0.17	N/A

Janux Therapeutics currently has a consensus price target of $36.46, suggesting a potential upside of 112.23%. Rocket Pharmaceuticals has a consensus price target of $7.77, suggesting a potential upside of 237.92%. Given Rocket Pharmaceuticals' higher possible upside, analysts clearly believe Rocket Pharmaceuticals is more favorable than Janux Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Janux Therapeutics	2 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.67
Rocket Pharmaceuticals	2 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.42

In the previous week, Rocket Pharmaceuticals had 10 more articles in the media than Janux Therapeutics. MarketBeat recorded 16 mentions for Rocket Pharmaceuticals and 6 mentions for Janux Therapeutics. Janux Therapeutics' average media sentiment score of 0.57 beat Rocket Pharmaceuticals' score of 0.25 indicating that Janux Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Janux Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rocket Pharmaceuticals	2 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

75.4% of Janux Therapeutics shares are owned by institutional investors. Comparatively, 98.4% of Rocket Pharmaceuticals shares are owned by institutional investors. 7.9% of Janux Therapeutics shares are owned by insiders. Comparatively, 21.3% of Rocket Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Janux Therapeutics' return on equity of -11.89% beat Rocket Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Janux Therapeutics	N/A	-11.89%	-11.13%
Rocket Pharmaceuticals	N/A	-52.77%	-44.92%

Summary

Janux Therapeutics beats Rocket Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

Get Rocket Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RCKT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RCKT vs. The Competition

Export

Metric	Rocket Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$272.24M	$3.93B	$7.27B	$13.21B
Dividend Yield	N/A	3.65%	2.52%	22.89%
P/E Ratio	-13.53	10.00	196.87	19.42
Price / Sales	N/A	1,149.11	562.72	81.54
Price / Cash	N/A	118.50	77.16	53.04
Price / Book	0.90	16.95	10.71	6.03
Net Income	-$223.12M	-$22.69M	$3.50B	$380.34M
7 Day Performance	-9.45%	-4.44%	-2.90%	-2.32%
1 Month Performance	-32.94%	-12.51%	-7.38%	-5.29%
1 Year Performance	-46.14%	7.77%	3.04%	-2.94%

Rocket Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RCKT Rocket Pharmaceuticals	2.966 of 5 stars	$2.30 -7.3%	$7.77 +237.9%	-33.7%	$272.24M	N/A	N/A	202
VOR Vor Biopharma	2.4514 of 5 stars	$18.58 -0.6%	$41.71 +124.5%	-41.0%	$1.11B	N/A	N/A	76
CVAC CureVac	N/A	$4.66 flat	N/A	N/A	$1.05B	$70.74M	6.47	880
IMTX Immatics	3.5145 of 5 stars	$7.73 +1.8%	$20.60 +166.5%	-32.3%	$1.04B	$54.60M	N/A	704	Analyst Forecast
MGTX MeiraGTx	3.0537 of 5 stars	$10.92 +1.2%	$24.71 +126.3%	+26.9%	$1.04B	$397.50M	15.38	393

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RCKT) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rocket Pharmaceuticals (RCKT) Competitors

RCKT vs. VOR, CVAC, IMTX, MGTX, and JANX

How does Rocket Pharmaceuticals compare to Vor Biopharma?

Summary

How does Rocket Pharmaceuticals compare to CureVac?

Summary

How does Rocket Pharmaceuticals compare to Immatics?

Summary

How does Rocket Pharmaceuticals compare to MeiraGTx?

Summary

How does Rocket Pharmaceuticals compare to Janux Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RCKT vs. The Competition

Rocket Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Rocket Pharmaceuticals (RCKT) Competitors

RCKT vs. VOR, CVAC, IMTX, MGTX, and JANX

How does Rocket Pharmaceuticals compare to Vor Biopharma?

Does the media prefer VOR or RCKT?

Is VOR or RCKT more profitable?

Which has more risk & volatility, VOR or RCKT?

Do analysts rate VOR or RCKT?

Do insiders and institutionals hold more shares of VOR or RCKT?

Which has stronger valuation and earnings, VOR or RCKT?

Summary

How does Rocket Pharmaceuticals compare to CureVac?

Which has preferable valuation & earnings, RCKT or CVAC?

Do analysts rate RCKT or CVAC?

Which has more volatility & risk, RCKT or CVAC?

Does the media favor RCKT or CVAC?

Is RCKT or CVAC more profitable?

Do institutionals & insiders hold more shares of RCKT or CVAC?

Summary

How does Rocket Pharmaceuticals compare to Immatics?

Do insiders & institutionals believe in RCKT or IMTX?

Which has better earnings & valuation, RCKT or IMTX?

Do analysts recommend RCKT or IMTX?

Does the media refer more to RCKT or IMTX?

Is RCKT or IMTX more profitable?

Which has more risk & volatility, RCKT or IMTX?

Summary

How does Rocket Pharmaceuticals compare to MeiraGTx?

Does the media refer more to RCKT or MGTX?

Is RCKT or MGTX more profitable?

Which has stronger valuation & earnings, RCKT or MGTX?

Do analysts rate RCKT or MGTX?

Do institutionals and insiders have more ownership in RCKT or MGTX?

Which has more volatility and risk, RCKT or MGTX?

Summary

How does Rocket Pharmaceuticals compare to Janux Therapeutics?

Which has more risk & volatility, JANX or RCKT?

Which has preferable valuation and earnings, JANX or RCKT?

Do analysts rate JANX or RCKT?

Does the media prefer JANX or RCKT?

Do insiders and institutionals hold more shares of JANX or RCKT?

Is JANX or RCKT more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RCKT vs. The Competition

Rocket Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools